Cover Image
市場調查報告書

學名藥的全球市場預測:2018年∼2028年

Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets

出版商 Visiongain Ltd 商品編碼 220569
出版日期 內容資訊 英文 254 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
學名藥的全球市場預測:2018年∼2028年 Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets
出版日期: 2018年04月25日 內容資訊: 英文 254 Pages
簡介

全球學名藥市場,2017年達到了2573億美元。該市場預計從2017年到2028年之間,以7.9%的年複合成長率擴大。

本報告提供全球學名藥市場相關調查,市場今後的預測和各地區趨勢,至2027年的收益預測,大企業的簡介等彙整資料。

第1章 報告概要

第2章 學名藥的簡介

  • 學名藥的隆盛
  • 所謂學名藥
  • 醫藥品產業概要
  • 生物學的同等性的確證
  • 學名藥的種類
  • 合成學名藥
  • 學名藥市場分類
  • 非專利的替代對大規模的醫藥品商務來說是壞消息嗎?
  • 對於學名藥法律規章
  • 強制授權
  • 市場定義和報告的範圍

第3章 學名藥市場

  • 市場概要
  • 全球市場的擴大
  • 各地區趨勢
  • 銷售額預測
  • 各地區市場的預測
  • 主要市場預測
  • 帶動成長的市場
  • 市場佔有率的變遷
  • 全球市場:促進因素與阻礙因素

第4章 美國的學名藥市場

第5章 歐洲的學名藥市場

第6章 亞太地區的學名藥市場

第7章 新興學名藥市場

  • 市場概要
  • 巴西
  • 俄羅斯
  • 墨西哥
  • 韓國
  • 土耳其

第8章 學名藥市場上大企業

  • 持續性擴大
  • Teva
  • Novartis
  • Mylan
  • Pfizer
  • Abbott
  • Sun Pharma
  • Aspen
  • Fresenius Kabi
  • Sanofi

第9章 學名藥市場定性分析

第10章 專家的意見

第11章 詞彙表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0305

Title:
GENERIC DRUGS MARKET FORECAST 2018-2028
Growth in Leading Regional and National Markets - North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico.

The generic drugs market is estimated at $257.3bn in 2017 and is expected to grow at a CAGR of 7.9% from 2017 to 2028. The generic drugs market is expected to grow at a CAGR of 7.2% in the second half of the forecast period.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 254-page report you will receive 66 tables and 84 figures- all unavailable elsewhere.

The 254-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Generic Drugs Market forecasts from 2018-2028

Generic Drugs Regional Market and National Market forecasts from 2018-2028, covering:

  • North America: US & Canada
  • Europe: Germany, UK, France, Italy, Spain, Rest of Europe
  • Asia-Pacific: Japan, Australia, India, China, South Korea, Rest of Asia-Pacific
  • Middle East & Africa: South Africa, Saudi Arabia, U.A.E, Rest of Middle East & Africa
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America

SWOT Analysis and Porter's Five Forces Analysis of the generic drugs market.

Assessment of selected leading companies that hold major market shares in the generic drugs market.

  • Teva
  • Novartis (Sandoz)
  • Allergan
  • Mylan
  • Pfizer
  • Abbott
  • Sun Pharma
  • Aspen
  • Fresenius Kabi
  • Sanofi
  • Dr. Reddy's Laboratories
  • Apotex

Visiongain's study is intended for anyone requiring commercial analyses for the Generic Drugs Market. You find data, trends and predictions.

Buy our report today ‘Generic Drugs Market Forecast 2018-2028: Growth in Leading Regional and National Markets - North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America, US, Canada, Germany, France, UK, Italy, Spain, India, China, Australia, South Korea, Japan, South Africa, Saudi Arabia, U.A.E, Brazil, Argentina, Mexico ’.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1. Global Generic Drugs: Market Overview
  • 1.2. Global Generic Drugs Market Segmentation
  • 1.3. Why You Should Read This Report
  • 1.4. How This Report Delivers
  • 1.5. Key Questions Answered by This Analytical Report
  • 1.6. Who is this Report for?
  • 1.7. Methodology
  • 1.8. Frequently Asked Questions (FAQs)
  • 1.9. Associated Visiongain Reports
  • 1.10. About Visiongain

2. An Introduction to Generic Drugs

  • 2.1. An Introduction to the Rise of Generic Drugs
  • 2.2. What Are Generic Drugs?
    • 2.2.1. Generic Active Ingredients
  • 2.3. A Brief Overview of the Pharmaceutical Industry
    • 2.3.1. Brief History of Generic Drugs
    • 2.3.2. The Hatch-Waxman Act: The Rise of Generics
  • 2.4. Demonstrating Bioequivalence: A Major Factor in Approving Generics
  • 2.5. Types of Generics - Authorised, Branded and Unbranded
  • 2.6. Complex Generics
  • 2.7. Classification of Generic Drugs Markets
  • 2.8. Is Generic Substitution Bad News for Big Pharma Business?
    • 2.8.1. The 'Ever greening' of Pharmaceutical Products
  • 2.9. Regulation of Generic Drugs
    • 2.9.1. Regulation in the US
      • 2.9.1.1. Obtaining FDA Approval: NDAs and ANDAs
      • 2.9.1.2. The Hatch-Waxman Act Title I: Promotion of Generic Drugs
      • 2.9.1.3. The Hatch-Waxman Act Title II: Incentives for the Branded Industry
      • 2.9.1.4. How Has the Hatch-Waxman Act Impacted upon the US Pharmaceutical Market?
      • 2.9.1.5. How the Timing of Market Entry Influences Product Success
    • 2.9.2. Regulation in Europe
      • 2.9.2.1. EU Marketing Approval Procedures
      • 2.9.2.2. The 8+2+1 Rule: EU Data Exclusivity
      • 2.9.2.3. Supplementary Protection Certificates
      • 2.9.2.4. Variation in Drug Development Regulations between European Countries
      • 2.9.2.5. The Move towards the Harmonisation of Standards
      • 2.9.2.6. The Impact of Europe's Unitary Patent System on Generic Drugs
      • 2.9.2.7. In or Out: Unitary Patent Strategy for European Generic Drug Manufacturing
    • 2.9.3. Regulation in Japan
    • 2.9.4. Regulation in China
  • 2.10. Compulsory Licensing
  • 2.11. Market Definition and Scope of This Report
    • 2.11.1. Market Sizing and Revenue Reporting

3. Generic Drugs Market 2017-2028

  • 3.1. The Global Generic Drugs Market: Market Overview
    • 3.1.1. Segmenting the Global Generic Drugs Market
  • 3.2. The Rise of the Global Generic Drugs Market in 2018
  • 3.3. The Global Generic Drugs Market: Sales Forecast 2017-2028
  • 3.4. Generic Drugs: Regional Market Forecast: 2017-2028
    • 3.4.1. Changes in Generic Drug Regional Market Shares 2017-2028
  • 3.5. National Markets That Will Drive Generic Drugs Growth
  • 3.6. Changes in Market Shares by National Market 2017-2028
  • 3.7. Drivers and Restraints for the Global Generic Drugs Market 2017-2028

4. North America Generic Drugs Market, 2017-2028

  • 4.1. Generic Drugs in the North America: Market Overview
    • 4.1.1. The Hatch-Waxman Act and Its Ongoing Effects
    • 4.1.2. Consolidation in the Drug Development and Supply Chain Driving North America Generics
  • 4.2. North America Generic Drugs Market: Drivers and Restraints 2017-2028
  • 4.3. North America Generic Drugs Market Forecast: 2017-2028
  • 4.4. Leading Companies Operating within the North America Generic Drugs Market
    • 4.4.1. Increasing Acceptance of Generics amongst Consumers
    • 4.4.2. Affordable Care Act: Expanding Medicare Coverage
  • 4.5. North America Generic Drugs Market - Strategic Analysis
    • 4.5.1. Will Biosimilars Dictate the Future of the US Generics Market?
    • 4.5.2. The Backlog of ANDA Applications
    • 4.5.3. The Generic Drug User Fee Amendments (GDUFA)
    • 4.5.4. Shortages of Generic Drugs Will Restrain the Market
    • 4.5.5. The Anti-Competitive ‘Pay for Delay' Effect
  • 4.6. US Generic Drugs Market: A Range of Factors Contributing to Growth
  • 4.7. Canada Generic Drugs Market: A Range of Factors Contributing to Growth
  • 4.8. North America Generic Drugs Market: Market Share Analysis

5. Europe Generic Drugs Market, 2017-2028

  • 5.1. Generic Drugs in the Europe: Market Overview
    • 5.1.1. Why Growth in Some Markets is Being Hindered?
    • 5.1.2. Predominant Pricing Systems and Generic Penetration in European Markets
      • 5.1.2.1. Lower Patient Co-Payments Drive Demand for Generics
      • 5.1.2.2. The Effects of Tendering for Generic Medicines
    • 5.1.3. Will Europe Move towards Free-Pricing Systems?
    • 5.1.4. Challenges in the European Regulatory Environment
    • 5.1.5. Ending Anti-Competitive ‘Pay for Delay' Tactics in Europe
    • 5.1.6. FDA and EMA Joint Data Sharing and Inspections
  • 5.2. Europe Generic Drugs Market Forecast: 2017-2028
  • 5.3. Germany Generic Drugs Market: New Reforms to Medicinal Pricing May Impact Market Entry
  • 5.4. UK Generic Drugs Market: A Mature Market with Growth Potentials
    • 5.4.1. Cost Pressures and Demand-Side Policies Drive UK Generic Penetration
  • 5.5. France Generic Drugs Market: Healthcare Reforms Impacting on Market Growth
  • 5.6. Italy Generic Drugs Market: Branded Generics Hindering Overall Growth
    • 5.6.1. The Tightening of Italy's Patent Legislations
    • 5.6.2. The Italian Healthcare System - A Tale of Falling Budgets
  • 5.7. Spain Generic Drugs Market: Room for Growth
    • 5.7.1. Cost-Containment Measures Helping to Boost Generic Drug Use
  • 5.8. Europe Generic Drugs Market: Market Share Analysis

6. Asia-Pacific Generic Drugs Market, 2017-2028

  • 6.1. Generic Drugs in the Asia-Pacific Market: Market Overview
  • 6.2. Indian Generic Drugs Market: Regulatory Failures Hindering Sales Growth
    • 6.2.1. Leading Companies in the Indian Generic Drugs Market
    • 6.2.2. Indian Generic Drugs Market: Sales Forecast 2017-2028
    • 6.2.3. The Reforms to India's Drug Prices Control Order and Its Likely Effects on Generic Drugs Revenues
    • 6.2.4. Expansion of the National Healthcare Coverage Increases the Need for Generics
    • 6.2.5. Has Recent Manufacturing Quality Failures Dented India's Generics Growth?
  • 6.3. Chinese Generic Drugs Market: Domestic Companies Dominate the Market Landscape
    • 6.3.1. The Major Drivers of Growth in the Chinese Generics Market
    • 6.3.2. Chinese Generic Drugs Market: Sales Forecast 2017-2028
    • 6.3.3. Compulsory Licensing of Generic Drugs
    • 6.3.4. Expansion of Healthcare Coverage and Reimbursement
    • 6.3.5. The Impacts of Price Controls and the Anhui Model
  • 6.4. Japanese Generic Drugs Market: High Barriers to Entry
    • 6.4.1. Public Perception of Generics in Japan
    • 6.4.2. Japanese Generic Drugs Market: Leading Companies
    • 6.4.3. Government Initiatives Driving Generic Penetration
    • 6.4.4. Japanese Attitudes to Generic Drugs
    • 6.4.5. Japanese Generic Drugs Market: Sales Forecast 2017-2028
  • 6.5. Australia Generic Drugs Market: Increased Market Access Supports the Market Growth
    • 6.5.1. Australia Generic Drugs Market: Sales Forecast 2017-2028
  • 6.6. South Korean Generic Drugs Market: Expected to Continue Its Trend of Growth
    • 6.6.1. Pharmaceutical Price Controls and Measures Being Implemented in South Korea
    • 6.6.2. KORUS FTA: The Free Trade Agreement between South Korea and the US
    • 6.6.3. The Free Trade Agreement between Korea and the European Union
    • 6.6.4. South Korean Generic Drugs Market: Sales Forecast 2017-2028
  • 6.7. Asia-Pacific Generic Drugs Market: Market Share Analysis

7. Middle-East & Africa Generic Drugs Market, 2017-2028

  • 7.1. Generic Drugs in the Middle-East & Africa Market: Market Overview
  • 7.2. South Africa Generic Drugs Market:
    • 7.2.1. South Africa Generic Drugs Market: Sales Forecast 2017-2028
  • 7.3. Saudi Arabia Generic Drugs Market:
    • 7.3.1. Saudi Arabia Generic Drugs Market: Sales Forecast 2017-2028
  • 7.4. UAE Generic Drugs Market:
    • 7.4.1. UAE Generic Drugs Market: Sales Forecast 2017-2028
  • 7.5. Middle-East & Africa Generic Drugs Market: Market Share Analysis

8. Latin America Generic Drugs Market, 2017-2028

  • 8.1. Generic Drugs in the Latin American Market: Market Overview
  • 8.2. Brazil Generic Drugs Market:
    • 8.2.1. Brazil Generic Drugs Market: Sales Forecast 2017-2028
  • 8.3. Argentina Generic Drugs Market:
    • 8.3.1. Argentina Generic Drugs Market: Sales Forecast 2017-2028
  • 8.4. Mexico Generic Drugs Market:
    • 8.4.1. Mexico Generic Drugs Market: Sales Forecast 2017-2028
  • 8.5. Latin America Generic Drugs Market: Market Share Analysis

9. Leading Companies in the Generic Drugs Market, 2017-2028

  • 9.1. Generic Drugs: Continuous Expansion to Rival
    • 9.1.1. The Leading Companies in the Global Generics Market
  • 9.2. Teva Pharmaceuticals Industries Limited
    • 9.2.1. Teva: Historical Financial and Performance Analysis, 2013-2017
    • 9.2.2. Teva Generic Drugs Sales Forecast 2017-2028
    • 9.2.3. Teva acquired Allergan's Generic Business Segment - Actavis Generic
      • 9.2.3.1. Further Entry into the Japanese Generics Market
    • 9.2.4. Teva: Generic Drugs Portfolio Analysis
      • 9.2.4.1. High-Value Generics to Drive Teva's Generics Growth?
      • 9.2.4.2. The Shift towards Innovation
      • 9.2.4.3. Copaxone Leads Teva's Moving Focus
      • 9.2.4.4. The Threat of Generic Erosion to Teva's Products
      • 9.2.4.5. Teva: What Future Moves Could We Expect?
  • 9.3. Novartis
    • 9.3.1. Novartis/Sandoz: Historical Financial and Performance Analysis, 2013-2017
    • 9.3.2. Novartis/Sandoz Generic Drugs Sales Forecast 2017-2028
    • 9.3.3. Novartis/Sandoz Generic Drugs Portfolio Analysis, 2017
      • 9.3.3.1. Emphasis on Difficult-to-Manufacture Products
      • 9.3.3.2. What Does the Future Hold for Novartis' Generic Drugs Business?
  • 9.4. Mylan
    • 9.4.1. Mylan: Historical Financial and Performance Analysis, 2012-2016
    • 9.4.2. Mylan Generic Drugs Sales Forecast 2017-2028
    • 9.4.3. Mylan: Recent Developments
      • 9.4.3.1. Acquisition of Meda AB
      • 9.4.3.2. Acquisition of Abbott's Generic Business
      • 9.4.3.3. Mylan's Growth in Manufacturing Capacity
      • 9.4.3.4. Mylan Acquires Rights to GSK's Advair, Diskus and Seretide
      • 9.4.3.5. The Race to Market Copaxone Generics
      • 9.4.3.6. Strategic Acquisition of Agila Expands Mylan's Injectables Business
    • 9.4.4. Mylan's Collaborative Efforts
      • 9.4.4.1. Biosimilar Collaboration with India's Biocon
      • 9.4.4.2. Biosimilar Collaborations with Momenta
      • 9.4.4.3. What Does the Future Hold for Mylan's Generic Drugs Business?
  • 9.5. Pfizer
    • 9.5.1. Pfizer: Historical Financial and Performance Analysis, 2012-2016
    • 9.5.2. Pfizer's Restructuring Strategy
    • 9.5.3. Pfizer's Done Deal with Hospira
    • 9.5.4. Pfizer Generic Drugs Sales Forecast 2017-2028
    • 9.5.5. Hospira: A Brief Overview of Operations
    • 9.5.6. Hospira: Historical Financial and Performance Analysis 2011-2015
    • 9.5.7. Hospira: Recent Developments
      • 9.5.7.1. Hospira's Expansion through Strategic Acquisitions
      • 9.5.7.2. Hospira: Manufacturing Concerns and Remediation Efforts
    • 9.5.8. Future Prospects for Pfizer's Generic Business
      • 9.5.8.1. The Pfizer-Allergan Deal Falls Through
      • 9.5.8.2. Activities of Allergan (Actavis) Prior to Mega-Merger
      • 9.5.8.3. Actavis' Work on Biosimilars
  • 9.6. Abbott
    • 9.6.1. Abbott: Historical Financial and Performance Analysis, 2014-2016
    • 9.6.2. Abbott Generic Drugs Sales Forecast 2017-2028
    • 9.6.3. Abbott: Recent Developments
      • 9.6.3.1. Abbott acquired St. Jude Medical
      • 9.6.3.2. Abbott after the Spin-Off of AbbVie - The Established Products Business Segment
      • 9.6.3.3. Acquisition of Solvay Pharmaceuticals and Piramal Healthcare Solutions
      • 9.6.3.4. Acquisition of CFR Pharmaceuticals Opens New Markets
    • 9.6.4. What Does the Future Hold for Abbott's Generic Drugs Business?
  • 9.7. Sun Pharma
    • 9.7.1. Sun Pharma's Business Areas
    • 9.7.2. Sun Pharma: Historical Financial and Performance Analysis, 2011-2015
    • 9.7.3. Sun Pharma Generic Drugs Sales Forecast 2017-2028
    • 9.7.4. Sun Pharma-Ranbaxy Acquisition
  • 9.8. Aspen
    • 9.8.1. Aspen: Historical Financial and Performance Analysis, 2012-2017
    • 9.8.2. Aspen Generic Sales Forecast 2017-2028
    • 9.8.3. Aspen: Recent Developments
      • 9.8.3.1. Aspen Acquires Merck MSD's Dutch API Plant
      • 9.8.3.2. Acquisition of GSK's Anti-Thrombosis Brands
      • 9.8.3.3. Future Outlook for Aspen's Generic Business
  • 9.9. Fresenius Kabi
    • 9.9.1. Fresenius Kabi: Historical Financial and Performance Analysis, 2011-2015
    • 9.9.2. Fresenius Kabi Generic Drugs Sales Forecast 2017-2028
    • 9.9.3. InnoPharma Licensing Deal Bolsters Portfolio Grown Via Past Acquisitions
    • 9.9.4. Fresenius Kabi's Joint Venture with PT Soho Global Health
    • 9.9.5. Future Prospects for Fresenius Kabi's Generics Business
  • 9.10. Sanofi
    • 9.10.1. Sanofi: Historical Financial and Performance Analysis, 2011-2015
    • 9.10.2. Sanofi Generic Sales Forecast 2017-2028
    • 9.10.3. Sanofi's Response to Lantus Competition
    • 9.10.4. Emerging Market Acquisitions
    • 9.10.5. Future Prospects for Sanofi's Generics Business
  • 9.11. Dr. Reddy's Laboratories Limited
    • 9.11.1. Dr. Reddy's: Historical Financial and Performance Analysis, 2015-2017
    • 9.11.2. Dr. Reddy's Generic Sales Forecast 2017-2028
    • 9.11.3. Dr. Reddy's launched generic Azacitidine for Injection in the Canadian Market
    • 9.11.4. The company acquired Imperial Credit Private Limited, a Non-Banking Finance Company
    • 9.11.5. Dr. Reddy's expanded its operations in the European region
  • 9.12. Apotex, Inc.
    • 9.12.1. Apotex expanded its manufacturing facilities in the U.S.
    • 9.12.2. Apotex launched first Generic Version of Merck's Nasonex

10. Qualitative Analysis of the Generic Drugs Market, 2017-2028

  • 10.1. Market Factors Influencing the Global Generic Drugs Market
  • 10.2. SWOT Analysis of the Global Generic Drugs Market, 2017-2028
    • 10.2.1. Strengths
      • 10.2.1.1. Improving Clarity around Regulatory Processes
      • 10.2.1.2. The Continuous Government Support for Generic Manufacturers - Precursors for Innovation
      • 10.2.1.3. Higher Pace of Growth Compared with Innovative Pharma
      • 10.2.1.4. Globalisation and Its Impact on Manufacturing Capabilities
    • 10.2.2. Weaknesses
      • 10.2.2.1. Safety and Quality Concerns in the Manufacturing Process
      • 10.2.2.2. The Non-Uniformity of Excipients
      • 10.2.2.3. The Uncertainty around Patent Extensions and Exclusivities
      • 10.2.2.4. Sceptical Physicians and the Negative Consumer Perception of Generics
      • 10.2.2.5. Inefficiencies in Certain Regulatory Approval Processes
    • 10.2.3. Opportunities
      • 10.2.3.1. Higher Value Biosimilars and Branded Generics
      • 10.2.3.2. Patent Expiries Creating Opportunities
      • 10.2.3.3. Changing Socio-Economic Conditions Impacting Generic Drugs Demand
      • 10.2.3.4. Emerging Markets - Expected to Drive Generics Volume Growth over Time
    • 10.2.4. Threats
      • 10.2.4.1. Government Cost-Cutting Initiatives Impacting on Generic Drugs Prices
      • 10.2.4.2. The Complexity Surrounding Patents and Patent Expiries
      • 10.2.4.3. Pharmacies and Healthcare Payer Consolidations
      • 10.2.4.4. Possible Impacts of a Declining Patent Pool
  • 10.3. Porter's Five Force Analysis of the Global Generic Drugs Market, 2017-2028
    • 10.3.1. Power of Buyers: Medium
    • 10.3.2. Power of Suppliers: Low
    • 10.3.3. Rivalry among Competitors: High
    • 10.3.4. Threat of New Entrants: High
    • 10.3.5. Threat of Substitutes: Low

11. Conclusions

  • 11.1. Overview of Current Market Conditions and Market Forecast, 2017-2028
  • 11.1. Generic Drugs as a Strategic Tool in Healthcare
  • 11.2. Major Drivers of Growth for Generic Drugs, 2017-2028
  • 11.3. The Regulatory Landscape for Generic Drugs
  • 11.4. Leading Generic Drug Manufacturers
  • 11.5. Future Outlook for the Leading Regions within the Global Generic Drugs Market, 2017-2028
  • 11.6. What Does the Future Hold for the Global Generic Drugs Market?
  • Appendices
  • Glossary
  • Some Associated Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 2.1: Types of Drug Names, 2017
  • Table 3.1: The Global Generic Drugs Market Size: Revenue ($bn) and Market Share (%) by Regional and National Markets, 2017 and 2018
  • Table 3.2: The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 3.3: The Global Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%) by Region, 2017-2028
  • Table 3.4: The Global Generic Drugs Market Forecast: Market Share (%) by Region, 2017, 2022, and 2028
  • Table 3.5: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2017-2022, 2022-2028, 2017-2028
  • Table 3.6: The Global Generic Drugs Market Forecast: Market Share (%) by National Markets, 2017, 2022, and 2028
  • Table 4.1: North America Generic Drugs Market: by Country Value ($bn), AGR (%), and CAGR (%), 2017 - 2028
  • Table 4.2: U.S. Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028
  • Table 4.3: Canada Generic Drugs Market Value ($bn), AGR (%), CAGR (%), 2017 - 2028
  • Table 5.1: Europe Generic Drugs Market: by Country Value ($bn), AGR (%) and CAGR (%) 2017 - 2028
  • Table 5.2: Germany Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028
  • Table 5.3: UK Generic Drugs Market Value ($bn), AGR (%) and CAGR (%) 2017 - 2028
  • Table 5.4: France Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028
  • Table 5.5: Italy Generic Drugs Market Value ($bn), AGR (%) and CAGR (%), 2017 - 2028
  • Table 5.6: Spain Generic Drugs Market Value ($bn), AGR (%), and CAGR (%), 2017 - 2028
  • Table 6.1: India Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 6.2: Leading Drug Types in Indian Pharmaceutical Market: Revenue ($bn) and Market Share (%), 2017, 2022 & 2028
  • Table 6.3: China Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 6.4: Japan Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 6.5: Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 6.6: South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 7.1: South Africa Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 7.2: Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 7.3: UAE Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 8.1: Brazil Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 8.2: Argentina Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 8.3: Mexico Generic Drugs Market Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 9.1: Top Generic Drugs Manufacturers: Total Revenue ($bn), Generic Drugs Revenue ($bn) and Generic Share of Revenue (%), 2016 and 2017
  • Table 9.2: Teva: Company Overview
  • Table 9.3: Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017
  • Table 9.4: Teva Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 9.5: Novartis: Overview
  • Table 9.6: Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017
  • Table 9.7: Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 9.8: Mylan: Company Overview
  • Table 9.9: Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2016
  • Table 9.10: Mylan: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 9.11: Pfizer: Company Overview
  • Table 9.12: Pfizer (Greenstone): Historical ‘Established Products' Drugs Sales ($bn) and AGR (%), 2014-2016
  • Table 9.13: Pfizer: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 9.14: Hospira: Company Overview
  • Table 9.15: Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
  • Table 9.16: Abbott: Company Overview
  • Table 9.17: Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2016
  • Table 9.18: Abbott: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 9.19: Sun Pharmaceuticals: Company Overview
  • Table 9.20: Sun Pharma: Historical Generic Drugs Sales ($bn), 2013-2017
  • Table 9.21: Sun Pharma Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 9.22: Aspen: Company Overview
  • Table 9.23: Aspen: Historical Revenue ($bn, bn Rand) and AGR (%), 2013-2017
  • Table 9.24: Aspen Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2017-2028
  • Table 9.25: Fresenius Kabi: Company Overview
  • Table 9.26: Fresenius Kabi: Historical Generic Drugs Sales ($bn), 2011-2015
  • Table 9.27: Fresenius Kabi: Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028
  • Table 9.28: Sanofi: Company Overview
  • Table 9.29: Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Table 9.30: Sanofi Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028
  • Table 9.31: Dr. Reddy's Laboratories Limited: Company Overview
  • Table 9.32: Dr. Reddy's: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017
  • Table 9.33: Dr. Reddy's Generic Drugs Forecast: Revenue ($bn), AGR (%) and CAGR (%), 2016-2028
  • Table 9.34: Apotex, Inc.: Company Overview
  • Table 10.1: SWOT Analysis of the Generic Drugs Market, 2017-2028
  • Table 11.1: Global Generic Drugs Market Forecast: Revenue ($bn) and CAGR (%), 2017, 2022 and 2028
  • Table 11.2: Top Generic Drug Manufacturers: Generic Drugs Revenue ($bn) and Market Share (%), 2017
  • Table 11.3: Global Generic Drugs Market Forecast: Revenue ($bn) by Regional Markets, 2017, 2022 and 2028

List of Figures

  • Figure 1.1: Global Generic Drugs Market Segmentation
  • Figure 2.1: EU Data Exclusivity for Generics: Possible Scenarios, 2017
  • Figure 3.1: The Global Generic Drugs Market Size: Revenue ($bn) by Regional Markets, 2017
  • Figure 3.2: The Global Generic Drugs Market Size: Revenue ($bn) by Regional Markets, 2018
  • Figure 3.3: The Global Generic Drugs Market Size: Revenue ($bn) by National Markets, 2017
  • Figure 3.4: The Global Generic Drugs Market Size: Revenue ($bn) by National Markets, 2018
  • Figure 3.5: Global Generic Drugs Market Forecast: ($bn) and AGR (%), 2017-2028
  • Figure 3.6: The Global Generic Drugs Market: Market Share (%) by Region, 2017
  • Figure 3.7: The Global Generic Drugs Market: Market Share (%) by Region, 2022
  • Figure 3.8: The Global Generic Drugs Market: Market Share (%) by Region, 2028
  • Figure 3.9: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2017-2022
  • Figure 3.10: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2022-2028
  • Figure 3.11: The Global Generic Drugs Market Forecast: CAGR (%) by National Market, 2017-2028
  • Figure 3.12: The Global Generic Drugs Market: Market Share (%) by National Markets, 2017
  • Figure 3.13: The Global Generic Drugs Market: Market Share (%) by National Markets, 2022
  • Figure 3.14: The Global Generic Drugs Market: Market Share (%) by National Markets, 2028
  • Figure 3.15: The Global Generic Drugs Market Drivers & Restraints, 2017-2028
  • Figure 4.1: North America Generic Drugs Market Drivers and Restraints, 2017-2028
  • Figure 4.2: North America Generic Drugs Market: by Country Value ($bn) and AGR (%) 2017 - 2028
  • Figure 4.3: U.S. Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028
  • Figure 4.4: Canada Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028
  • Figure 4.5: North America Generic Drugs Market, % Country Share, 2017
  • Figure 4.6: North America Generic Drugs Market, % Country Share, 2022
  • Figure 4.7: North America Generic Drugs Market, % Country Share, 2028
  • Figure 5.1: Europe Generic Drugs Market: by Country Value ($ bn) and AGR (%) 2017 - 2028
  • Figure 5.2: Germany Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028
  • Figure 5.3: UK Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028
  • Figure 5.4: France Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028
  • Figure 5.5: Italy Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028
  • Figure 5.6: Spain Generic Drugs Market Value ($bn) and AGR (%) 2017 - 2028
  • Figure 5.7: Europe Generic Drugs Market, % Country Share, 2017
  • Figure 5.8: Europe Generic Drugs Market, % Country Share, 2022
  • Figure 5.9: Europe Generic Drugs Market, % Country Share, 2028
  • Figure 6.1: Asia-Pacific Generic Drugs Market Forecast: Revenue ($bn), 2017-2028
  • Figure 6.2: India Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 6.3: Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2017
  • Figure 6.4: Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2022
  • Figure 6.5: Leading Drug Types in Indian Pharmaceutical Market: Market Share (%), 2028
  • Figure 6.6: China Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 6.7: Japan Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 6.8: Australia Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2017-2028
  • Figure 6.9: South Korean Generic Drugs Market Forecast: Revenue ($bn), AGR (%), 2017-2028
  • Figure 6.10: Asia-Pacific Generic Drugs Market, % Country Share, 2017
  • Figure 6.11: Asia-Pacific Generic Drugs Market, % Country Share, 2022
  • Figure 6.12: Asia-Pacific Generic Drugs Market, % Country Share, 2028
  • Figure 7.1: Middle-East & Africa Generic Drugs Market Forecast: Revenue ($bn), 2017-2028
  • Figure 7.2: South Africa Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 7.3: Saudi Arabia Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 7.4: UAE Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 7.5: Middle-East & Africa Generic Drugs Market, % Country Share, 2017
  • Figure 7.6: Middle-East & Africa Generic Drugs Market, % Country Share, 2022
  • Figure 7.7: Middle-East & Africa Generic Drugs Market, % Country Share, 2028
  • Figure 8.1: Latin America Generic Drugs Market Forecast: Revenue ($bn), 2017-2028
  • Figure 8.2: Brazil Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 8.3: Argentina Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 8.4: Mexico Generic Drugs Market Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 8.5: Latin America Generic Drugs Market, % Country Share, 2017
  • Figure 8.6: Latin America Generic Drugs Market, % Country Share, 2022
  • Figure 8.7: Latin America Generic Drugs Market, % Country Share, 2028
  • Figure 9.1: Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2016
  • Figure 9.2: Top Generic Drugs Manufacturers: Generic Drugs Revenue ($bn), 2017
  • Figure 9.3: Teva: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017
  • Figure 9.4: Teva Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 9.5: Novartis/Sandoz: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017
  • Figure 9.6: Novartis/Sandoz Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 9.7: Mylan: Historical Generic Drugs Sales ($bn) and AGR (%), 2012-2016
  • Figure 9.8: Mylan: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 9.9: Pfizer: Historical ‘Established Products' Drugs Sales ($bn) and AGR (%), 2014-2016
  • Figure 9.10: Pfizer Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 9.11: Hospira: Historical Specialty Injectables Sales ($bn) and AGR (%), 2011-2015
  • Figure 9.12: Abbott: Historical Generic Drugs Sales ($bn) and AGR (%), 2014-2016
  • Figure 9.13: Abbott Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 9.14: Sun Pharma: Historical Generic Drugs Sales ($bn) and AGR (%), 2013-2017
  • Figure 9.15: Sun Pharma Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 9.16: Aspen: Historical Revenue ($bn) and AGR (%), 2013-2017
  • Figure 9.17: Aspen: Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 9.18: Fresenius Kabi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 9.19: Fresenius Kabi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2016-2028
  • Figure 9.20: Sanofi: Historical Generic Drugs Sales ($bn) and AGR (%), 2011-2015
  • Figure 9.21: Sanofi Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2016-2028
  • Figure 9.22: Dr. Reddy's: Historical Generic Drugs Sales ($bn) and AGR (%), 2015-2017
  • Figure 9.23: Dr. Reddy's Generic Drugs Forecast: Revenue ($bn) and AGR (%), 2017-2028
  • Figure 10.1: Porter's Five Force Analysis of the Global Generic Drugs Market, 2017
  • Figure 11.1: Global Generic Drugs Market Forecast: Revenue ($bn), 2017 2022 and 2028

Companies Listed

  • Abbott
  • AbbVie
  • Able Laboratories
  • Aché
  • Actavis
  • Alcon (Novartis)
  • Allergan (Actavis)
  • Amgen
  • Anda Inc
  • Apotex
  • APP Pharmaceuticals
  • Arrow Group (Actavis)
  • Ascent Pharmahealth (Actavis)
  • ASKA Pharmaceuticals
  • Aspen
  • AstraZeneca
  • Aurobindo
  • Auspex Pharmaceuticals
  • Bedford Laboratories
  • Bergamo (Amgen)
  • Biocon
  • Bioniche Pharma (Mylan)
  • BMP Sunstone (Sanofi)
  • Caraco
  • Celltrion
  • CFR Pharmaceuticals (Abbott)
  • Cipla
  • Claris
  • Dabur Pharma (Fresenius Kabi)
  • Daiichi Sankyo
  • Dalim BioTech
  • Dr Reddy's Laboratory
  • Ebewe Pharma (Novartis)
  • Eden Biopharm Group
  • Egis
  • Elder Pharmaceuticals (Torrent Pharmaceuticals)
  • Eli Lilly
  • Elyson Pharmaceuticals
  • EMS Sigma Pharma
  • Eon Labs
  • Eurofarma Laboratories
  • Farmacias Similares
  • Fenwal (Fresenius Kabi)
  • Forest Laboratories (Actavis)
  • Foshan Chanbende Development
  • Fougera Pharmaceuticals (Novartis)
  • Fresenius Kabi
  • Fresenius SE & Co
  • Fuji Pharma
  • Gavis Pharmaceuticals
  • Gedeon Richter
  • Genfar S.A (Sanofi)
  • Genzyme (Sanofi)
  • Gilead Sciences
  • GlaxoSmithKline (GSK)
  • Greenstone (Pfizer)
  • Grupo Sanborns
  • Grupo Uriach
  • Hexal
  • Hospira (Pfizer)
  • IDEV Technologies (Abbott)
  • Ilsung Pharmaceuticals
  • Imperial Credit Private Limited
  • InnoPharma Inc
  • Itero Biopharmaceuticals
  • Janssen
  • Javelin Pharmaceuticals (Hospira)
  • Johnson & Johnson
  • Kmart
  • KMS Pharmaceutical
  • Kowa Pharmaceuticals
  • Krka
  • Labesfal Genéricos (Fresenius Kabi)
  • Laboratorio Sanderson (Fresenius Kabi)
  • Laboratorios Best
  • Laboratorios Kendrick (Sanofi)
  • Lek (Novartis)
  • Lundbeck
  • Lupin
  • Matrix Laboratories
  • Mayne Pharma (Hospira)
  • Meda AB
  • Medley (Sanofi)
  • Merck KGaA
  • MN Pharma (Amgen)
  • Momenta Pharmaceuticals
  • Mylan
  • Natco Pharma
  • Nexus Pharmaceuticals
  • Nichi-Iko
  • Nippon Chemiphar
  • Novartis (Sandoz)
  • Novo Nordisk
  • OptiMedica (Abbott)
  • Orchid Chemicals & Pharmaceuticals
  • Oriel Therapeutics (Novartis)
  • Parenteral Drugs India Ltd
  • Perrigo
  • Pfizer
  • Piramal (Abbott Laboratories)
  • Pliva (Teva)
  • PT Soho Global Health
  • Ranbaxy (Sun Pharmaceuticals)
  • Ratiopharm
  • Rimsa
  • Roche
  • Sabex (Novartis)
  • Sanofi
  • Sawai Pharmaceuticals
  • Schein Pharmaceutical (Actavis)
  • Servier
  • Shelys (Aspen)
  • Sigma Pharmaceuticals (Aspen)
  • Solvay Pharmaceuticals (Abbott)
  • Specifar Pharmaceuticals (Actavis)
  • St. Jude Medical
  • STADA Arzneimittel
  • Strides Arcolab
  • Sun Pharma
  • Synthon
  • Taiyo Pharmaceuticals
  • Takeda
  • Teuto Brasileiro (Pfizer)
  • Teva
  • The Laboratory of Analytical Services International Ltd
  • Towa
  • UDL Laboratories
  • Uteron Pharma (Actavis)
  • Valeant Pharmaceuticals
  • Wal-Mart
  • Warner Chilcott (Actavis)
  • Watson
  • Wockhardt
  • Wyeth (Pfizer)
  • Zentiva (Sanofi)
  • Zhejiang Chiral Medicine Chemicals Co. Ltd
  • Zhejiang Hisun Pharmaceutical
  • Zydus Cadila

List of Organisations Mentioned in the Report:

  • Assogenerici [Italy]
  • Blue Cross Blue Shield Association (BCBSA) [US]
  • British Generic Manufacturers Association (BGMA)
  • Caisse Nationale de l'Assurance Maladie (CNAM) [France]
  • Center for Drug Evaluation and Research (CDER) [US]
  • Centers for Medicare and Medicaid Services [US]
  • China Food and Drug Administration (CFDA)
  • COFEPRIS [Mexico]
  • Competion and Markets Authority (CMA) [UK]
  • Congressional Budget Office (CBO) [US]
  • European Commission
  • European Generics Medicines Association (EGA)
  • European Medicines Agency (EMA)
  • European Patent Office (EPO)
  • Export Council of Australia
  • Federal Commission for the Protection against Sanitary Risk (COFEPRIS)
  • Federal Trade Commission (FTC) [US]
  • Food and Drugs Administration (FDA) [US]
  • General Adminsistratioon of Quality Supervision, Inspection and Quarantine (AQSIQ) [China]
  • General Directorate of Pharmaceuticals and Pharmacy (GDPP) [Turkey]
  • Generic Pharmaceutical Association (GPhA)
  • Gesundheitsberichterstattung des Bundes (Federal Health Monitoring System, Germany)
  • Medical Technology Association of Australia
  • Medicine and Healthcare products Regulatory Agency (MHRA)
  • Ministry of Health, Labour and Welfare (MHLW) [Japan]
  • Ministry of Human Resources and Social Security (MOHRSS)
  • National Development and Reform Commission (NDRC)
  • National Health Service (NHS)
  • National Pharmaceutical Pricing Authority [India]
  • Pan American Health Organization (PAHO)
  • Pharmaceutical and Medical Devices Agency (PMDA) [Japan]
  • Queen Mary University of London
  • Servicio Sanitario Nazionale (SSN) [Italy]
  • United Nations' Department of Economic and Social Affairs
  • US Generic Pharmaceutical Association (GPhA)
  • Veropharm (Abbott)
  • World Health Organization (WHO)
  • World Trade Organisation (WTO)
Back to Top